Entera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program
03 avr. 2023 07h00 HE
|
Entera Bio Ltd.
JERUSALEM, April 03, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today...